Agency Resources | NILA Advocacy
In November 2015 the Centers for Medicare and Medicaid Services (CMS) overhauled the coding and payment rates for drugs of abuse testing under Medicare's Part B Clinical Laboratory Fee Schedule (CLFS).
NILA believes CMS's final determinations disproportionately reduced payments to reference laboratories specializing in definitive testing.
For more information, see below:
CMS Preliminary Determinations for Definitive Drug Test Pricing, September 30, 2016, View/Download PDF
CY 2016 Clinical Laboratory Fee Schedule (CLFS) Final Determinations for Drug Testing. View/Download PDF
November 23, 2016
Final Determinations for Repricing Definitive Drug Tests
September 11, 2018
Curbing Drug Addiction and the Opioid Crisis, NILA White Paper, Press Release
August 8, 2016
NILA Comments to Support Reconsideration for Final Payment Determinations for Toxicology Codes G0840, G0481, G0482, G0483. View/Download PDF.
- Supporting Documents: Immunoassay Process , LC-MS/MS Process
|July 18, 2016, NILA testifies at Public Meeting Regarding New and Reconsidered Clinical Diagnostic Laboratory Test Codes for the Clinical Laboratory Fee Schedule for Calendar Year 2017 / Advisory Panel on Clinical Diagnostic Laboratory Tests||
Announcement of the Advisory Panel on Clinical Diagnostic Laboratory Tests Meeting. View/download PDF.
Agenda for the Advisory Panel on Clinical Diagnostic Laboratory Tests Meeting. View/download PDF.
July 18, 2016, Clinical Laboratory Public Meeting YouTube Video (Morning Session – 3:29:10) NILA Testimony: 45:28 - 54:36. View video here.
July 18, 2016, Clinical Laboratory Public Meeting YouTube Video (Afternoon Session – 1:39:21) Panel Discussion: 1:43:42, Reporting of Vote: 2:13:00. View video here.
November 23, 2015
NILA Comments on New CMS Payments for Drug Tests. View/Download PDF.